141 completed, 44 terminated, 14 recruiting, 13 active not recruiting. 83 Phase 1, 75 Phase 2, 32 Not applicable, 23 Phase 3, 2 Early Phase 1.
Follow Leukemia, Hairy Cell: new trials by email Literature Review of Leukemia, Hairy Cell trials Research Report on Leukemia, Hairy Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma | Not yet recruiting | IRCCS San Raffaele | 64 | 2026-11-01 | 2026-08-13 | |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Assessment of Disease Burden in Hairy Cell Leukemia Peripheral and BM blood sample - Hairy Cell Leukemia | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 45 | 2025-01-01 | 2025-01-17 |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2024-12-16 | 2026-09-09 |
| Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management Hairy Cell Leukemia (HCL) | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 50 | 2024-12-12 | 2025-01-14 | |
| Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management Hairy Cell Leukemia (HCL) | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 50 | 2024-12-05 | 2025-01-08 | |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-09-09 | 2026-09-09 |
| Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients Hairy Cell Leukemia | Unknown | Power Life Sciences Inc. | 500 | 2024-06-01 | 2023-05-16 | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Terminated | Kite, A Gilead Company | 19 | 2022-11-01 | 2026-03-10 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Epcoritamab, Lenalidomide, Ibrutinib - Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Genmab | 264 | 2022-06-14 | 2026-07-07 |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant CD22CART cell infusion - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2022-05-23 | 2026-10-16 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 102 | 2022-02-21 | 2025-01-20 | |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 60 | 2021-07-19 | 2026-02-13 |
| B-cell Chronic Lymphoid Malignancies Markers Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma | Unknown | University Hospital, Strasbourg, France | 420 | 2021-06-14 | 2021-07-07 |
Showing 20 of 237. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (190) · Lymphoma, Follicular (174) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (174) · Lymphoma, B-Cell, Marginal Zone (172) · Lymphoma, Mantle-Cell (171) · Burkitt Lymphoma (167) · Lymphoma, Large B-Cell, Diffuse (166) · Lymphoma, Non-Hodgkin (164) · Lymphoma, Large-Cell, Immunoblastic (153) · Hodgkin Disease (149) · Lymphoma, T-Cell, Cutaneous (143) · Multiple Myeloma (138) · Leukemia, Myeloid, Acute (136) · Mycosis Fungoides (133)
Hematologic Diseases (237) · Hemic and Lymphatic Diseases (237) · Immune System Diseases (237) · Immunoproliferative Disorders (237) · Lymphatic Diseases (237) · Neoplasms by Histologic Type (237) · Lymphoproliferative Disorders (216) · Neoplasms (201) · Pathologic Processes (200) · Pathological Conditions, Signs and Symptoms (200) · Disease Attributes (198) · Chronic Disease (193) · Leukemia, Lymphoid (193) · Leukemia, B-Cell (190) · Lymphoma, B-Cell (181)
Peripheral Blood Stem Cell Transplantation (26) · Rituximab (20) · Cyclophosphamide (18) · fludarabine phosphate (17) · Mycophenolic Acid (16) · Cyclosporine (14) · Tacrolimus (14) · Whole-Body Irradiation (12) · Filgrastim (11) · Etoposide (10) · Flow Cytometry (10) · Psychiatric Rehabilitation (10) · Therapeutics (10) · Busulfan (8) · Methotrexate (8)
National Cancer Institute (NCI) (34) · Fred Hutchinson Cancer Center (28) · City of Hope Medical Center (12) · Memorial Sloan Kettering Cancer Center (9) · Northwestern University (7) · Barbara Ann Karmanos Cancer Institute (6) · Case Comprehensive Cancer Center (6) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Mayo Clinic (5) · OHSU Knight Cancer Institute (5) · Vanderbilt-Ingram Cancer Center (5) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (4) · Jonsson Comprehensive Cancer Center (4) · M.D. Anderson Cancer Center (4) · University of Medicine and Dentistry of New Jersey (4)
United States (199) · Italy (19) · Germany (15) · France (13) · Canada (9) · Switzerland (8) · Belgium (7) · Israel (6) · Spain (6) · South Korea (5) · United Kingdom (5) · Czechia (4) · Netherlands (4) · Slovakia (4) · Turkey (Türkiye) (4)
Robert J Kreitman, M.D. (9) · David Maloney (5) · Brenda Sandmaier (4) · Robert Kreitman, MD (4) · Lucia Catani, PhD (3) · Paul Martin (3) · Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · Brian J. Bolwell, MD (2) · Elisabeth Paietta, PhD (2) · Jae Park, MD (2) · John A. Glaspy, MD, MPH (2) · Jorge Cortes, MD (2) · Joseph Bubalo, PharmD, BCPS, BCOP (2) · Kenneth G. Lucas, MD (2)
PMID 32499241, PMID 18596230, PMID 41980020, PMID 10552943, PMID 10764422, PMID 11474661, PMID 15459300, PMID 17020988, PMID 17397698, PMID 18327587, PMID 18603561, PMID 18989154, PMID 19170225, PMID 19841031, PMID 19900571, PMID 21719601, PMID 21745173, PMID 21821712, PMID 22259028, PMID 22355053, PMID 22480131, PMID 23358983, PMID 23393050, PMID 24474568, PMID 24530972, PMID 25092772, PMID 26175532, PMID 26213141, PMID 26352686, PMID 26700120, PMID 26700123, PMID 26853648, PMID 27020837, PMID 27118452, PMID 28314788, PMID 28817727, PMID 29072975, PMID 29292843, PMID 29487070, PMID 30205939, PMID 30562587, PMID 31298972, PMID 31481800, PMID 31617432, PMID 32109194, PMID 32628342, PMID 32818466, PMID 33420905, PMID 33627164, PMID 33754642
P30CA015704 (12), P30CA033572 (8), P30CA043703 (7), P30CA015083 (6), P30CA068485 (6), P30CA072720 (6), P01CA018029 (4), P30CA022453 (4), P01CA078902 (3), P30CA006973 (3), P30CA016058 (3), P30CA016672 (3), U01CA076576 (3), U01CA097452 (3), N01CM00039 (2)